Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

被引：1
作者：
Younes, Anas [1 ]
Copeland, Amanda [2 ]
Fanale, Michelle A. [3 ]
Hagemeister, Fredrick [4 ]
Fayad, Luis [5 ]
Pro, Barbara [6 ]
Faria, Silvana C.
Ji, Yuan [7 ]
Medeiros, L. Jeffrey
Berry, Donald A.
Buglio, Daniela [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Clin Invest & Translat Res Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Ctr Hymphoma Myeloma, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Ctr Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Div Quantitat Sci, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.1763.1763
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1617 / 1617
页数：1
相关论文
共 50 条
  • [31] Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).
    Duvic, Madeleine
    Becker, Juergen C.
    Dalle, Stephane
    Vanaclocha, Francisco
    Bernengo, Maria Grazia
    Lebbe, Celeste
    Dummer, Reinhard
    Hirawat, Samit
    Zhang, Lei
    Marshood, Miriam
    Laird, Glen
    Prince, H. Miles
    BLOOD, 2008, 112 (11) : 370 - 370
  • [32] Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma
    Tobinai, K
    Hotta, T
    Saito, H
    Ohnishi, K
    Ohno, R
    Ogura, M
    Ariyoshi, Y
    Takeyama, K
    Kobayashi, T
    Ohashi, Y
    Shirakawa, S
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1996, 26 (06) : 455 - 460
  • [33] A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma
    Bond, David A.
    Huang, Ying
    Christian, Beth A.
    Jaglowski, Samantha
    Benson, Don
    Alinari, Lapo
    Baiocchi, Robert A.
    Cohen, Jonathon B.
    Blum, Kristie A.
    Maddocks, Kami J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1750 - 1753
  • [34] Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
    Patrick B. Johnston
    Lauren C. Pinter-Brown
    Ghulam Warsi
    Kristen White
    Radhakrishnan Ramchandren
    Experimental Hematology & Oncology, 7
  • [35] Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
    Johnston, Patrick B.
    Pinter-Brown, Lauren C.
    Warsi, Ghulam
    White, Kristen
    Ramchandren, Radhakrishnan
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [36] A PHASE II INTERNATIONAL, MULTICENTER STUDY OF ORAL PANOBINOSTAT (LBH589) IN PATIENTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)
    Bernengo, M. G.
    Vanaclocha, F.
    Duvic, M.
    Kuzel, T.
    Kerdel, F.
    Pinter-Brown, L.
    Bosly, A.
    Okada, C.
    Breneman, D.
    Zinzani, P. L.
    Becker, J.
    Hughey, L.
    Ardaiz, M.
    Zain, J.
    Zhang, L.
    Hirawat, S.
    Laird, G.
    Johnson, D.
    Prince, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 109 - 109
  • [37] Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
    Ribrag, Vincent
    Caballero, Dolores
    Ferme, Christophe
    Zucca, Emanuele
    Arranz, Reyes
    Briones, Javier
    Gisselbrecht, Christian
    Salles, Gilles
    Gianni, Alessandro M.
    Gomez, Henry
    Kahatt, Carmen
    Corrado, Claudia
    Szyldergemajn, Sergio
    Extremera, Sonia
    de Miguel, Bernardo
    Cullell-Young, Martin
    Cavalli, Franco
    HAEMATOLOGICA, 2013, 98 (03) : 357 - 363
  • [38] Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
    Yee, Karen W. L.
    Zeng, Zhihong
    Konopleva, Marina
    Verstovsek, Srdan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Thomas, Deborah
    Wierda, William
    Apostolidou, Efrosyni
    Albitar, Maher
    O'Brien, Susan
    Andreeff, Michael
    Giles, Francis J.
    CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5165 - 5173
  • [39] A PHASE II TRIAL OF THE ORAL MTOR INHIBITOR EVEROLIMUS IN RELAPSED NON-HODGKIN LYMPHOMA (NHL) AND HODGKIN DISEASE (HD)
    Witzig, E.
    Habermann, T.
    Reeder, C.
    Micallef, I.
    Ansell, S.
    Porrata, L.
    Johnston, P.
    LaPlant, B.
    Kabat, B.
    Zent, C.
    Zeldenrust, S.
    Inwards, D.
    Colgan, J.
    Call, T.
    Markovic, S.
    Tun, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 436 - 436
  • [40] Phase II trial for lenalidomide alone in relapsed/refractory aggressive non-Hodgkin lymphoma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05) : 339 - 339
12345